Navigation Links
Former Telomolecular CEO Clarifies SEC Settlement
Date:11/3/2008

Former Telomolecular CEO, Matthew Sarad, clarifies the scope and terms of his settlement with the SEC. Case No. 2:08-cv-2252-GEB-DAD.

(PRWEB) November 3, 2008 -- Telomolecular, a Rancho Cordova, California Corporation, was formed in 2005 to develop and license new nanotechnology based therapeutics to treat diseases of aging and cancer, particularly diseases related to chromosomal telomere shortening. The Company worked with a number of known U.S. universities and hospitals including but not limited to Stanford, the University of Nebraska, and the third largest hospital in the country, the Cleveland Clinic, where Telomolecular's anticancer therapeutics are being presently studied in living animals. The SEC alleged in a complaint (Case No. 2:08-cv-2252-GEB-DAD) filed in a Sacramento, California court in September of 2008, that the Corporation's Chief Executive Officer, Mr. Matthew Sarad, misrepresented key facts to investors related to the number and involvement level of certain employees, the corporation's progress towards an IPO, and two material financial transactions. Without admitting or denying the charges Mr. Sarad reached a settlement that required that he pay a $100,000 fine and not serve as an officer or director of a publicly traded U.S. company for a period of five years.

According to Mr. Sarad, "I had no practical way to litigate the government and just wanted to put this unfortunate episode of my career behind me. Resigning from Telomolecular was truly heartbreaking for me given the many years of very hard work. We were all working in the interests of our investors and in the interests of science. The number of extraordinary assets and opportunities the company possesses is impressive and I believe the new CEO will break into global pharmaceutical markets with our cutting edge goods. Telomolecular was, and is one of the most important and most promising technology companies in the country working on truly revolutionary nanotechnology based pharmaceutical products."

In approximately two years time, Mr. Sarad stated that he managed to acquire many valuable licenses to certain patented and patent pending medical biotechnologies developed by prestigious universities such as Stanford University, Northeastern, and the University of Nebraska. He built, from the ground floor up, an operational nanotechnology laboratory and staffed it with scientists that formerly served at some of the nation's finest research institutes such as Harvard Medical School, M.D. Anderson Cancer Center, and U.C. Davis Cancer Center. With the help of his partners, the company established internal manufacturing capacity and began to sell nanotechnology based cosmetic goods just before his departure. The Corporation sponsored $1 million worth of medical research at the University of Nebraska and the Cleveland Clinic Hospital, where some of its cancer and aging products are being tested for safety and efficacy in animals, and maybe soon in people. Early results have been very promising, demonstrating high levels of safe and non-toxic remission in a number of key malignancies such as breast and prostate cancer.

Mr. Sarad said the company was the first to deliver active human telomerase and synthetic DNA nanocircles to human cells and observe significant signs of telomere regeneration that was not observed when delivering inactive telomerase or linear strands of the same DNA. Studies performed by UCLA suggest that the elongation of chromosomal telomeres might prove to be effective and safe in the treatment of HIV in humans, while studies by other hospitals and universities suggest that certain diseases of aging might respond positively to telomere elongation. The company had also made advances in the delivery of intact RNA to cells through a process known as RNA protein shielding, it had recently begun to work on the development of therapeutics for diseases of the mitochondria, and it had developed new kinds of biodegradable nanoparticle based gene delivery technologies.

###

Read the full story at http://www.prweb.com/releases/2008/11/prweb1466514.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
3. David Barker, Former Illumina CSO, Joins GenVaults Scientific Advisory Board
4. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
7. Former Patent Office Solicitor and Judge Joins Rothwell Figg
8. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
9. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
10. Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility
11. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" ... clinical data from its phase 1/2 tendon repair study investigating ... (RCT-01) as a treatment for Achilles tendinosis. ... The clinical trial ... 6 months and showed no serious adverse events related to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, ... proteomics analysis platform developed in the laboratory of Dr. James Heath at ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team ... vascular grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. ... of treating coronary artery disease (CAD). Lam is an assistant professor at the ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
Breaking Biology News(10 mins):